Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 11 | 2024 | 129 | 2.770 |
Why?
|
| Infection Control | 8 | 2024 | 76 | 1.640 |
Why?
|
| Klebsiella pneumoniae | 6 | 2021 | 38 | 1.500 |
Why?
|
| Bacteremia | 5 | 2019 | 53 | 1.280 |
Why?
|
| Clostridium Infections | 2 | 2023 | 19 | 0.980 |
Why?
|
| Klebsiella Infections | 5 | 2020 | 35 | 0.900 |
Why?
|
| Skin | 5 | 2025 | 73 | 0.830 |
Why?
|
| Catheter-Related Infections | 3 | 2014 | 16 | 0.820 |
Why?
|
| Communicable Diseases | 1 | 2023 | 7 | 0.790 |
Why?
|
| Intensive Care Units | 6 | 2024 | 119 | 0.780 |
Why?
|
| Bacterial Proteins | 6 | 2025 | 48 | 0.770 |
Why?
|
| beta-Lactamases | 6 | 2025 | 42 | 0.760 |
Why?
|
| Virus Diseases | 1 | 2022 | 6 | 0.720 |
Why?
|
| Subacute Care | 1 | 2021 | 4 | 0.700 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2021 | 7 | 0.660 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2021 | 20 | 0.660 |
Why?
|
| Humans | 24 | 2025 | 12240 | 0.620 |
Why?
|
| Baths | 3 | 2024 | 19 | 0.600 |
Why?
|
| Chlorhexidine | 3 | 2024 | 29 | 0.590 |
Why?
|
| Hospitals | 5 | 2024 | 68 | 0.490 |
Why?
|
| Medical Informatics | 1 | 2016 | 4 | 0.490 |
Why?
|
| Population Surveillance | 3 | 2015 | 46 | 0.440 |
Why?
|
| Hospital Information Systems | 1 | 2014 | 3 | 0.430 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2024 | 40 | 0.410 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2015 | 55 | 0.410 |
Why?
|
| Staphylococcal Infections | 2 | 2015 | 81 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 4 | 2024 | 207 | 0.350 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 18 | 0.320 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 16 | 0.320 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2010 | 26 | 0.320 |
Why?
|
| Nursing Homes | 3 | 2025 | 27 | 0.310 |
Why?
|
| Neutropenia | 1 | 2008 | 8 | 0.280 |
Why?
|
| Retrospective Studies | 3 | 2023 | 1467 | 0.270 |
Why?
|
| Anus Diseases | 1 | 2008 | 2 | 0.270 |
Why?
|
| Ulcer | 1 | 2008 | 2 | 0.270 |
Why?
|
| United States | 5 | 2023 | 989 | 0.260 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2024 | 26 | 0.240 |
Why?
|
| Chicago | 4 | 2024 | 453 | 0.240 |
Why?
|
| Male | 9 | 2025 | 6815 | 0.210 |
Why?
|
| Health Facilities | 1 | 2024 | 12 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2024 | 26 | 0.200 |
Why?
|
| Female | 8 | 2025 | 6974 | 0.180 |
Why?
|
| Catheterization, Central Venous | 2 | 2014 | 9 | 0.180 |
Why?
|
| Algorithms | 2 | 2014 | 169 | 0.180 |
Why?
|
| Multilocus Sequence Typing | 1 | 2021 | 8 | 0.180 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 324 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2021 | 39 | 0.170 |
Why?
|
| Phylogeny | 1 | 2021 | 35 | 0.170 |
Why?
|
| Dermatomycoses | 1 | 2021 | 4 | 0.170 |
Why?
|
| Candida | 1 | 2021 | 9 | 0.170 |
Why?
|
| Candidiasis | 1 | 2021 | 13 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 126 | 0.170 |
Why?
|
| Adult | 6 | 2024 | 3557 | 0.160 |
Why?
|
| Ecosystem | 1 | 2021 | 13 | 0.160 |
Why?
|
| Epidemiological Monitoring | 2 | 2024 | 10 | 0.160 |
Why?
|
| Aged | 6 | 2025 | 4000 | 0.160 |
Why?
|
| Middle Aged | 5 | 2024 | 4043 | 0.160 |
Why?
|
| Quality Improvement | 2 | 2024 | 78 | 0.150 |
Why?
|
| Carrier State | 2 | 2024 | 29 | 0.150 |
Why?
|
| Hospitalization | 2 | 2024 | 158 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 74 | 0.140 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 14 | 0.140 |
Why?
|
| Genomics | 3 | 2023 | 26 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2010 | 827 | 0.120 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 2 | 0.120 |
Why?
|
| Critical Illness | 1 | 2015 | 53 | 0.110 |
Why?
|
| Management Audit | 1 | 2014 | 2 | 0.110 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 8 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 2152 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2014 | 66 | 0.100 |
Why?
|
| Equipment Contamination | 1 | 2012 | 5 | 0.090 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 7 | 0.090 |
Why?
|
| Skin Care | 2 | 2024 | 10 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2010 | 15 | 0.080 |
Why?
|
| Single-Blind Method | 1 | 2010 | 46 | 0.080 |
Why?
|
| Disease Reservoirs | 1 | 2010 | 8 | 0.080 |
Why?
|
| Hand Disinfection | 1 | 2010 | 8 | 0.080 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2010 | 6 | 0.080 |
Why?
|
| Enterococcus | 1 | 2010 | 24 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 71 | 0.080 |
Why?
|
| Rectum | 2 | 2024 | 21 | 0.080 |
Why?
|
| Sentinel Surveillance | 1 | 2008 | 4 | 0.070 |
Why?
|
| Disease Notification | 1 | 2008 | 2 | 0.070 |
Why?
|
| Gram-Positive Cocci | 1 | 2008 | 4 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2008 | 12 | 0.070 |
Why?
|
| Hospitals, Urban | 1 | 2008 | 16 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 84 | 0.070 |
Why?
|
| Registries | 1 | 2008 | 88 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 99 | 0.070 |
Why?
|
| Sexuality | 1 | 2008 | 10 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2008 | 156 | 0.070 |
Why?
|
| Risk Factors | 1 | 2010 | 1049 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 423 | 0.060 |
Why?
|
| Time Factors | 1 | 2008 | 695 | 0.060 |
Why?
|
| Adolescent | 1 | 2008 | 989 | 0.060 |
Why?
|
| Metagenomics | 1 | 2025 | 3 | 0.060 |
Why?
|
| Bacteria | 1 | 2025 | 34 | 0.050 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2024 | 9 | 0.050 |
Why?
|
| Microbiota | 1 | 2025 | 35 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 28 | 0.050 |
Why?
|
| Feces | 1 | 2024 | 40 | 0.050 |
Why?
|
| Iodophors | 1 | 2024 | 3 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2024 | 10 | 0.050 |
Why?
|
| Universal Precautions | 1 | 2024 | 6 | 0.050 |
Why?
|
| California | 1 | 2024 | 27 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2024 | 11 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2024 | 77 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 5 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2023 | 5 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2023 | 23 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2023 | 21 | 0.050 |
Why?
|
| Carbapenems | 1 | 2019 | 11 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 78 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 161 | 0.040 |
Why?
|
| Critical Care | 1 | 2018 | 49 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 651 | 0.030 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2015 | 8 | 0.030 |
Why?
|
| Illinois | 1 | 2015 | 110 | 0.030 |
Why?
|
| Prevalence | 1 | 2015 | 175 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 277 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 101 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 312 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2014 | 10 | 0.030 |
Why?
|
| Hospital Administration | 1 | 2014 | 13 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 39 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 50 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2014 | 38 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2014 | 56 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2018 | 1478 | 0.020 |
Why?
|
| Bacterial Load | 1 | 2012 | 10 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2012 | 24 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 252 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 400 | 0.020 |
Why?
|